Prognostic impact of the inclusion of uPA/PAI-1 tumor levels in the current adjuvant treatment decision-making for early breast cancer - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Future Oncology Année : 2014

Prognostic impact of the inclusion of uPA/PAI-1 tumor levels in the current adjuvant treatment decision-making for early breast cancer

(1) , (1) , (1) , (1) , (2, 1) , (1) , (1) , (1, 3) , (1) , (1, 2)
1
2
3

Résumé

AIMS: Following the introduction of new adjuvant therapies we wanted to reappraise the prognostic and predictive value of uPA/PAI-1 in early breast cancer. PATIENTS & METHODS: This monocentric retrospective study included 652 patients who had curative surgery between 2006 and 2011 and adjuvant treatment decision-making, taking into account uPA/PAI-1 tumor levels. RESULTS: uPA and PAI-1 levels were associated with classical clinicopathological parameters and adjuvant chemotherapy decision, but not with peritumoral vascular invasion (PVI; also known as peritumoral vascular emboli). HER2 overexpression, PVI and uPA/PAI-1 levels were not significantly associated with relapse-free survival in univariate analysis. In multivariate analysis, T stage, N stage and progesterone receptors were the only independent relapse-free survival predictive factors. CONCLUSION: The absence of an association between uPA/PAI-1 and PVI allows their concomitant consideration in adjuvant treatment discussion. The overall good prognosis of patients with high uPA/PAI-1 levels might be linked to the uPA/PAI-1 predictive value and the inclusion of these parameters in adjuvant guidelines.
Fichier non déposé

Dates et versions

hal-02181364 , version 1 (12-07-2019)

Identifiants

Citer

H. Saadoun, P. J. Lamy, S. Thezenas, S. Pouderoux, Frédéric Bibeau, et al.. Prognostic impact of the inclusion of uPA/PAI-1 tumor levels in the current adjuvant treatment decision-making for early breast cancer. Future Oncology, 2014, 10, pp.195--209. ⟨10.2217/fon.13.177⟩. ⟨hal-02181364⟩
48 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More